TriangleCabozantinib (NCT05263050)
Cabozantinib trial for Metastatic Renal Cell Carcinoma (NCT05263050). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for people over eighteen with advanced kidney cancer, or well-differentiated grade one–three neuroendocrine tumors progressing within twelve months after somatostatin analogs or when those drugs are unsuitable. Previous cabozantinib is excluded.
The idea: cabozantinib blocks growth and blood-vessel signals. Oral dosing starts at forty milligrams daily and is adjusted in steps. Only the first-line kidney-cancer combination cohort adds monthly nivolumab infusions. Researchers assess dosing, safety, and cancer control.
This phase 2 study plans 111 patients. Matthew Zibelman leads at Fox Chase Cancer Center in Philadelphia, the sole recruiting US site.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.